• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Roivant Sciences Ltd.

    11/14/24 4:31:06 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ROIV alert in real time by email
    SC 13G/A 1 sayw24111430_13ga.htm



     UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934*

    (Amendment No. 3)

    Roivant Sciences Ltd.
    (Name of Issuer)

    Common Shares, $0.0000000341740141 par value per share
    (Title of Class of Securities)

    G76279101
    (CUSIP Number)

    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)
    ☐ Rule 13d-1(c)
    ☒ Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    CUSIP No. G76279101
    13G
    Page 2 of 24 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    Viking Global Investors LP
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    54,099,066*
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    54,099,066*
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    54,099,066*
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    7.3%*
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     

    *See Item 4


    CUSIP No. G76279101
    13G
    Page 3 of 24 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    Viking Global Performance LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    26,500,847*
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    26,500,847*
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    26,500,847*
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    3.6%*
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

    *See Item 4
     

    CUSIP No. G76279101
    13G
    Page 4 of 24 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    Viking Global Equities II LP
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    530,019*
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    530,019*
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    530,019*
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    0.1%*
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     

    *See Item 4


    CUSIP No. G76279101
    13G
    Page 5 of 24 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    Viking Global Equities Master Ltd.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Cayman Islands
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    25,970,828*
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    25,970,828*
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    25,970,828*
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    3.5%*
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    CO
     
     
     
     

    *See Item 4


    CUSIP No. G76279101
    13G
    Page 6 of 24 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    Viking Long Fund GP LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    8,638,772*
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    8,638,772*
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     

    8,638,772*

     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    1.2%*
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

    *See Item 4
     

    CUSIP No. G76279101
    13G
    Page 7 of 24 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    Viking Long Fund Master Ltd.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Cayman Islands
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    8,638,772*
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    8,638,772*
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    8,638,772*
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    1.2%*
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    CO
     
     
     
     

    *See Item 4
     

    CUSIP No. G76279101
    13G
    Page 8 of 24 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    Viking Global Opportunities Parent GP LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    18,959,447*
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    18,959,447*
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    18,959,447*
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    2.6%*
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

    * See Item 4


    CUSIP No. G76279101
    13G
    Page 9 of 24 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    Viking Global Opportunities GP LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    18,959,447*
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    18,959,447*
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    18,959,447*
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    2.6%*
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

    * See Item 4

    CUSIP No. G76279101
    13G
    Page 10 of 24 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    Viking Global Opportunities Portfolio GP LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    18,959,447*
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    18,959,447*
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    18,959,447*
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    2.6%*
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

     * See Item 4


    CUSIP No. G76279101
    13G
    Page 11 of 24 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    Viking Global Opportunities Illiquid Investments Sub-Master LP
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Cayman Islands
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    18,959,447*
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    18,959,447*
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    18,959,447*
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    2.6%*
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     

    * See Item 4


    CUSIP No. G76279101
    13G
    Page 12 of 24 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    O. Andreas Halvorsen
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Norway
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    54,099,066*
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    54,099,066*
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    54,099,066*
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    7.3%*
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     

    *See Item 4


    CUSIP No. G76279101
    13G
    Page 13 of 24 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    David C. Ott
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United States
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    54,099,066*
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    54,099,066*
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    54,099,066*
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    7.3%*
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     

    *See Item 4


    CUSIP No. G76279101
    13G
    Page 14 of 24 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    Rose S. Shabet
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United States
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    54,099,066*
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    54,099,066*
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    54,099,066*
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    7.3%*
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     

    *See Item 4
     

    CUSIP No. G76279101
    13G
    Page 15 of 24 Pages
    Item 1(a).
    Name of Issuer:

    Roivant Sciences Ltd. (the “Issuer”)

    Item 1(b).
    Address of Issuer’s Principal Executive Offices:

    7th Floor
    50 Broadway, London SW1H 0DB,
    United Kingdom

    Item 2(a).
    Name of Person Filing:

    Viking Global Investors LP (“VGI”),
    Viking Global Performance LLC (“VGP”),
    Viking Global Equities II LP (“VGEII”),
    Viking Global Equities Master Ltd. (“VGEM”),
    Viking Long Fund GP LLC (“VLFGP”),
    Viking Long Fund Master Ltd. (“VLFM”),
    Viking Global Opportunities Parent GP LLC (“Opportunities Parent”),
    Viking Global Opportunities GP LLC (“Opportunities GP”),
    Viking Global Opportunities Portfolio GP LLC (“Opportunities Portfolio GP”),
    Viking Global Opportunities Illiquid Investments Sub-Master LP (“VGOP”),
    O. Andreas Halvorsen, David C. Ott and Rose S. Shabet (collectively, the “Reporting Persons”)

    Items 2(b).
    Address of Principal Business Office or, if none, Residence:

    The business address of each of the Reporting Persons is: 600 Washington Boulevard, Floor 11, Stamford, Connecticut 06901.

    Items 2(c).
    Citizenship:
     
    VGI and VGEII are Delaware limited partnerships; VGP, VLFGP, Opportunities Parent, Opportunities GP and Opportunities Portfolio GP are Delaware limited liability companies; VGEM and VLFM are Cayman Islands exempted companies; VGOP is a Cayman Islands exempted limited partnership; O. Andreas Halvorsen is a citizen of Norway; and David C. Ott and Rose S. Shabet are citizens of the United States.

    Item 2(d).
    Titles of Classes of Securities:

    Common shares, par value $0.0000000341740141 per share (“Common Shares”)
     
    Item 2(e).
    CUSIP NUMBER: G76279101

    Item 3.
    If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:


    (a)
    ☐ Broker or dealer registered under Section 15 of the Exchange Act

    (b)
    ☐ Bank as defined in Section 3(a)(6) of the Exchange Act

    (c)
    ☐ Insurance company as defined in Section 3(a)(19) of the Exchange Act

    (d)
    ☐ Investment company registered under Section 8 of the Investment Company Act of 1940

    (e)
    ☐ Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940: see Rule 13d-1(b)(1)(ii)(E)


    CUSIP No. G76279101
    13G
    Page 16 of 24 Pages

    (f)
    ☐ Employee Benefit Plan, Pension Fund which is subject to the provisions of the Employee Retirement Income Security Act of 1974 or Endowment Fund; see Rule 13d-1(b)(1)(ii)(F)

    (g)
    ☐ Parent holding company, in accordance with Rule 13d-1(b)(1)(ii)(G).

    (h)
    ☐ Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act.

    (i)
    ☐ Church Plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940.

    (j)
    ☐ Non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

    (k)
    ☐ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

    Item 4.
    Ownership

    The percentages set forth herein are based on 739,521,824 Common Shares outstanding as of August 6, 2024, as reported by the Issuer in its quarterly report on Form 10-Q, filed with the U.S. Securities and Exchange Commission (the “Commission”) on August 9, 2024.

    A. VGI


    (a) Amount beneficially owned: 54,099,066



    (b) Percent of Class: 7.3%



    (c) Number of shares as to which such person has:


    (i) Sole power to vote or to direct the vote: 0



    (ii) Shared power to vote or to direct the vote: 54,099,066



    (iii) Sole power to dispose or to direct the disposition of: 0



    (iv) Shared power to dispose or to direct the disposition of: 54,099,066



    VGI provides managerial services to VGEII, VGEM, VLFM and VGOP. VGI has the authority to dispose of and vote the Common Shares directly owned by VGEII, VGEM, VLFM and VGOP. VGI does not directly own any Common Shares.



    Based on Rule 13d-3 of the Act, VGI may be deemed to beneficially own the Common Shares directly held by VGEII, VGEM, VLFM and VGOP.

    B. VGP


    (a) Amount beneficially owned: 26,500,847



    (b) Percent of Class: 3.6%



    (c)  Number of shares as to which such person has:




    (i) Sole power to vote or to direct the vote: 0



    (ii) Shared power to vote or to direct the vote: 26,500,847



    (iii) Sole power to dispose or to direct the disposition of: 0
     

    (iv) Shared power to dispose or to direct the disposition of: 26,500,847


    CUSIP No. G76279101
    13G
    Page 17 of 24 Pages
     
    VGP, as the general partner of VGEII, has the authority to dispose of and vote the Common Shares directly owned by VGEII. VGP serves as investment manager to VGEM and has the authority to dispose of and vote the Common Shares directly owned by VGEM. VGP does not directly own any Common Shares.
       
     
    Based on Rule 13d-3 of the Act, VGP may be deemed to beneficially own the Common Shares directly held by VGEII and VGEM.

    C. VGEII

     
    (a) Amount beneficially owned: 530,019
       
     
    (b) Percent of Class: 0.1%
       
     
    (c)  Number of shares as to which such person has:

     
    (i) Sole power to vote or to direct the vote: 0
       
     
    (ii) Shared power to vote or to direct the vote: 530,019
       
     
    (iii) Sole power to dispose or to direct the disposition of: 0
       
     
    (iv) Shared power to dispose or to direct the disposition of: 530,019
       
     
    VGEII has the authority to dispose of and vote the Common Shares directly owned by it, which power may be exercised by its general partner, VGP, and by VGI, an affiliate of VGP, which provides managerial services to VGEII.

    D. VGEM


    (a) Amount beneficially owned: 25,970,828

     

    (b) Percent of Class: 3.5%

     

    (c)  Number of shares as to which such person has:


    (i) Sole power to vote or to direct the vote: 0



    (ii) Shared power to vote or to direct the vote: 25,970,828



    (iii) Sole power to dispose or to direct the disposition of: 0



    (iv) Shared power to dispose or to direct the disposition of: 25,970,828



    VGEM has the authority to dispose of and vote the Common Shares directly owned by it, which power may be exercised by its investment manager, VGP, and by VGI, an  affiliate of VGP, which provides managerial services to VGEM. Viking Global Equities LP (a Delaware limited partnership) and Viking Global Equities III Ltd. (a Cayman Islands exempted company), through its investment in VGE III Portfolio Ltd. (a Cayman Islands exempted company), invest substantially all of their assets through VGEM.


    CUSIP No. G76279101
    13G
    Page 18 of 24 Pages
    E. VLFGP


    (a) Amount beneficially owned: 8,638,772



    (b) Percent of Class: 1.2%



    (c)  Number of shares as to which such person has:


    (i) Sole power to vote or to direct the vote: 0



    (ii) Shared power to vote or to direct the vote: 8,638,772



    (iii) Sole power to dispose or to direct the disposition of: 0



    (iv) Shared power to dispose or to direct the disposition of: 8,638,772



    VLFGP serves as the investment manager of VLFM and has the authority to dispose of and vote the Common Shares directly owned by VLFM. VLFGP does not directly own any Common Shares.



    Based on Rule 13d-3 of the Act, VLFGP may be deemed to beneficially own the Common Shares directly held by VLFM.

    F. VLFM


    (a) Amount beneficially owned: 8,638,772



    (b) Percent of Class: 1.2%



    (c)  Number of shares as to which such person has:


    (i) Sole power to vote or to direct the vote: 0



    (ii) Shared power to vote or to direct the vote: 8,638,772



    (iii) Sole power to dispose or to direct the disposition of: 0



    (iv) Shared power to dispose or to direct the disposition of: 8,638,772



    VLFM has the authority to dispose of and vote the Common Shares directly owned by it, which power may be exercised by its investment manager, VLFGP, and by VGI, an affiliate of VLFGP, which provides managerial services to VLFM. Viking Long Fund LP (a Delaware limited partnership) and Viking Long Fund III Ltd. (a Cayman Islands exempted company), through its investment in Viking Long Fund Intermediate L.P. (a Cayman Islands limited partnership), invest substantially all of their assets through VLFM.

    G. Opportunities Parent
     
     
    (a) Amount beneficially owned: 18,959,447
       
     
    (b) Percent of Class: 2.6%
       
     
    (c)  Number of shares as to which such person has:

     
    (i) Sole power to vote or to direct the vote: 0
       
     
    (ii) Shared power to vote or to direct the vote: 18,959,447
       
     
    (iii) Sole power to dispose or to direct the disposition of: 0


    CUSIP No. G76279101
    13G
    Page 19 of 24 Pages

    (iv) Shared power to dispose or to direct the disposition of: 18,959,447



    Opportunities Parent is the sole member of Opportunities GP, which has the authority to dispose of and vote the Common Shares controlled by Opportunities Portfolio GP, which consists of the Common Shares directly held by VGOP. Opportunities Parent does not directly own any Common Shares.



    Based on Rule 13d-3 of the Act, Opportunities Parent may be deemed to beneficially own the Common Shares directly held by VGOP.

    H. Opportunities GP


    (a) Amount beneficially owned: 18,959,447



    (b) Percent of Class: 2.6%



    (c)  Number of shares as to which such person has:


    (i) Sole power to vote or to direct the vote: 0



    (ii) Shared power to vote or to direct the vote: 18,959,447



    (iii) Sole power to dispose or to direct the disposition of: 0



    (iv) Shared power to dispose or to direct the disposition of: 18,959,447



    Opportunities GP serves as the sole member of Opportunities Portfolio GP and has the authority to dispose of and vote the Common Shares controlled by Opportunities Portfolio GP, which consists of the Common Shares directly held by VGOP. Opportunities GP does not directly own any Common Shares.



    Based on Rule 13d-3 of the Act, Opportunities GP may be deemed to beneficially own the Common Shares directly held by VGOP.

    I. Opportunities Portfolio GP


    (a) Amount beneficially owned: 18,959,447



    (b) Percent of Class: 2.6%



    (c)  Number of shares as to which such person has:


    (i) Sole power to vote or to direct the vote: 0

     

    (ii) Shared power to vote or to direct the vote: 18,959,447

     

    (iii) Sole power to dispose or to direct the disposition of: 0

     

    (iv) Shared power to dispose or to direct the disposition of: 18,959,447

     

    Opportunities Portfolio GP serves as the general partner of VGOP and has the authority to dispose of and vote the Common Shares directly owned by VGOP. Opportunities Portfolio GP does not directly own any Common Shares.

     

    Based on Rule 13d-3 of the Act, Opportunities Portfolio GP may be deemed to beneficially own the Common Shares directly held by VGOP.


    CUSIP No. G76279101
    13G
    Page 20 of 24 Pages
    J. VGOP


    (a) Amount beneficially owned: 18,959,447



    (b) Percent of Class: 2.6%



    (c)  Number of shares as to which such person has:


    (i) Sole power to vote or to direct the vote: 0



    (ii) Shared power to vote or to direct the vote: 18,959,447



    (iii) Sole power to dispose or to direct the disposition of: 0



    (iv) Shared power to dispose or to direct the disposition of: 18,959,447



    VGOP has the authority to dispose of and vote the Common Shares directly owned by it, which power may be exercised by its general partner, Opportunities Portfolio GP, and by VGI, an affiliate of Opportunities Portfolio GP, which provides managerial services to VGOP.



    Viking Global Opportunities LP (a Delaware limited partnership) and Viking Global Opportunities III LP (a Cayman Islands exempted limited partnership), through its investment in Viking Global Opportunities Intermediate LP (a Cayman Islands exempted limited partnership), invest substantially all of their assets in Viking Global Opportunities Master LP (a Cayman Islands exempted limited partnership), which in turn invests through VGOP.

    K. O. Andreas Halvorsen, David C. Ott and Rose S. Shabet


    (a) Amount beneficially owned: 54,099,066



    (b) Percent of Class: 7.3%



    (c)  Number of shares as to which such person has:


    (i) Sole power to vote or to direct the vote: 0



    (ii) Shared power to vote or to direct the vote: 54,099,066



    (iii) Sole power to dispose or to direct the disposition of: 0



    (iv) Shared power to dispose or to direct the disposition of: 54,099,066



    Mr. Halvorsen, Mr. Ott and Ms. Shabet, as Executive Committee Members of Viking Global Partners LLC (general partner of VGI), VGP, VLFGP and Opportunities Parent, have shared authority to dispose of and vote the Common Shares beneficially owned by VGI, VGP, VLFGP and Opportunities Parent. None of Mr. Halvorsen, Mr. Ott and Ms. Shabet directly owns any Common Shares.
     

    Based on Rule 13d-3 of the Act, each may be deemed to beneficially own the Common Shares directly held by VGEII, VGEM, VLFM and VGOP.



    Mr. Halvorsen, Mr. Ott and Ms. Shabet each beneficially own 54,099,066 Common Shares consisting of (i) 530,019 Common Shares directly and beneficially owned by VGEII, (ii) 25,970,828 Common Shares directly and beneficially owned by VGEM, (iii) 8,638,772 Common Shares directly and beneficially owned by VLFM and (iv) 18,959,447 Common Shares directly and beneficially owned by VGOP.




    CUSIP No. G76279101
    13G
    Page 21 of 24 Pages
    Item 5.
    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owners of more than five percent of the class of securities, check the following [ ].

    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.

    The response to Item 4 is incorporated by reference herein.

    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

    Not applicable.

    Item 8.
    Identification and Classification of Members of the Group.
     
    Not applicable.

    Item 9.
    Notice of Dissolution of Group.
     
    Not applicable.

    Item 10.
    Certification. (if filing pursuant to Rule 13d-1(d))

    Not applicable.


    CUSIP No. G76279101
    13G
    Page 22 of 24 Pages
    SIGNATURES

    After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

    Dated: November 14, 2024








    By:
    /s/ Scott M. Hendler


    Name:
    Scott M. Hendler on behalf of O. Andreas Halvorsen (1)



    By:
    /s/ Scott M. Hendler


    Name:
    Scott M. Hendler on behalf of David C. Ott (2)



    By:
    /s/ Scott M. Hendler


    Name:
    Scott M. Hendler on behalf of Rose S. Shabet (3)
     
    (1) Scott M. Hendler is signing on behalf of O. Andreas Halvorsen, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES II LP and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD., and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737).

    (2) Scott M. Hendler is signing on behalf of David C. Ott, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES II LP and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD., and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Ott on February 12, 2021 (SEC File No. 005-49737).

    (3) Scott M. Hendler is signing on behalf of Rose S. Shabet, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES II LP and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD., and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Ms. Shabet on February 12, 2021 (SEC File No. 005-49737).


    CUSIP No. G76279101
    13G
    Page 23 of 24 Pages
    EXHIBIT A - JOINT FILING AGREEMENT

    This joint filing agreement is made and entered into as of this 14th day of November, 2024, by and among VIKING GLOBAL INVESTORS LP, VIKING GLOBAL PERFORMANCE LLC, VIKING GLOBAL EQUITIES II LP, VIKING GLOBAL EQUITIES MASTER LTD., VIKING LONG FUND GP LLC, VIKING LONG FUND MASTER LTD., VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, O. Andreas Halvorsen, David C. Ott and Rose S. Shabet.

    The parties to this Agreement hereby agree to prepare jointly and file timely (and otherwise to deliver as appropriate) all filings on any Forms 3, 4, or 5 or Schedules 13D or 13G, and any and all amendments thereto and any other documents relating thereto (collectively, the “Filings”) as required to be filed pursuant to the Securities Exchange Act of 1934, as amended. The parties to this Agreement further agree and covenant that each will fully cooperate with such other parties in the preparation, timely filing, and delivery of all such Filings.

    IN WITNESS WHEREOF, the parties hereto have executed this agreement as of the date first set forth above.

    Dated: November 14, 2024








    By:
    /s/ Scott M. Hendler


    Name:
    Scott M. Hendler on behalf of O. Andreas Halvorsen (1)



    By:
    /s/ Scott M. Hendler


    Name:
    Scott M. Hendler on behalf of David C. Ott (2)



    By:
    /s/ Scott M. Hendler


    Name:
    Scott M. Hendler on behalf of Rose S. Shabet (3)

    (1) Scott M. Hendler is signing on behalf of O. Andreas Halvorsen, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES II LP and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD., and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737).

    (2) Scott M. Hendler is signing on behalf of David C. Ott, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES II LP and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD., and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Ott on February 12, 2021 (SEC File No. 005-49737).


    CUSIP No. G76279101
    13G
    Page 24 of 24 Pages
    (3) Scott M. Hendler is signing on behalf of Rose S. Shabet, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES II LP and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD., and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Ms. Shabet on February 12, 2021 (SEC File No. 005-49737).



    Get the next $ROIV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ROIV

    DatePrice TargetRatingAnalyst
    2/15/2024$17.00Outperform
    Wolfe Research
    1/5/2024$20.00Overweight
    Piper Sandler
    12/12/2023$14.00Buy
    Deutsche Bank
    10/17/2023$17.00Buy
    Guggenheim
    6/8/2023$10.50Neutral
    BofA Securities
    10/27/2022$7.00Overweight
    JP Morgan
    5/23/2022$6.00Outperform
    SVB Leerink
    4/29/2022$15.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $ROIV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 2025

      BASEL, Switzerland and LONDON and NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 29, 2025, to report its financial results for the fourth quarter and fiscal year ended March 31, 2025, and provide a business update. To access the conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under "Events & Presentations" in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events. The archived webcast will be available on Roivant's website after the conferen

      5/15/25 4:10:00 PM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402

      Eric Venker, M.D. (currently President and COO of Roivant) appointed as CEO of Immunovant and Tiago Girao appointed as CFO of ImmunovantPete Salzmann, M.D. retired from his role as Immunovant CEO and DirectorLeadership change is part of a broader strategic transition with Roivant increasing operational involvement and strategic oversight of Immunovant  IND cleared for a potentially registrational program for IMVT-1402 in SjD, its fifth and potentially best-in-class indication with positive in-class competitor data from Phase 2 studies suggesting a correlation between depth of IgG reduction and degree of clinical improvement; study expected to initiate in summer 2025Proof-of-concept study of

      4/21/25 7:00:00 AM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

      Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a 4.7 point improvement in the lower dose arm (with 64% mean IgG reduction) Initial CIDP results from Period 1, following standard of care washout, demonstrate a mean improvement in the adjusted INCAT disability score of 1.8 across batoclimab arms and an 84% responder rate in those patients who achieved an IgG lowering greater than 70% In both batoclimab studies, deeper IgG reductions correlated with better clinical outcomes across a range of assessments and timepoints INDs active for both MG and C

      3/19/25 7:45:00 AM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ROIV
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Roivant Sciences Ltd.

      SCHEDULE 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)

      5/15/25 6:53:25 PM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Roivant Sciences Ltd.

      SCHEDULE 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)

      5/15/25 5:29:42 PM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Roivant Sciences Ltd.

      SCHEDULE 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)

      5/15/25 4:35:35 PM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ROIV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Roivant Sciences Ltd.

      SC 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)

      11/14/24 4:31:06 PM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Roivant Sciences Ltd.

      SC 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)

      11/12/24 4:58:58 PM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Roivant Sciences Ltd.

      SC 13G - Roivant Sciences Ltd. (0001635088) (Subject)

      11/12/24 10:34:18 AM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ROIV
    Financials

    Live finance-specific insights

    See more
    • Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 2025

      BASEL, Switzerland and LONDON and NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 29, 2025, to report its financial results for the fourth quarter and fiscal year ended March 31, 2025, and provide a business update. To access the conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under "Events & Presentations" in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events. The archived webcast will be available on Roivant's website after the conferen

      5/15/25 4:10:00 PM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402

      Eric Venker, M.D. (currently President and COO of Roivant) appointed as CEO of Immunovant and Tiago Girao appointed as CFO of ImmunovantPete Salzmann, M.D. retired from his role as Immunovant CEO and DirectorLeadership change is part of a broader strategic transition with Roivant increasing operational involvement and strategic oversight of Immunovant  IND cleared for a potentially registrational program for IMVT-1402 in SjD, its fifth and potentially best-in-class indication with positive in-class competitor data from Phase 2 studies suggesting a correlation between depth of IgG reduction and degree of clinical improvement; study expected to initiate in summer 2025Proof-of-concept study of

      4/21/25 7:00:00 AM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

      Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a 4.7 point improvement in the lower dose arm (with 64% mean IgG reduction) Initial CIDP results from Period 1, following standard of care washout, demonstrate a mean improvement in the adjusted INCAT disability score of 1.8 across batoclimab arms and an 84% responder rate in those patients who achieved an IgG lowering greater than 70% In both batoclimab studies, deeper IgG reductions correlated with better clinical outcomes across a range of assessments and timepoints INDs active for both MG and C

      3/19/25 7:45:00 AM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ROIV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CFO Pulik Richard covered exercise/tax liability with 3,487 shares, decreasing direct ownership by 0.86% to 402,212 units (SEC Form 4)

      4 - Roivant Sciences Ltd. (0001635088) (Issuer)

      5/22/25 9:00:39 PM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President & COO Venker Eric covered exercise/tax liability with 39,148 shares, exercised 100,000 shares at a strike of $3.85 and sold $1,095,000 worth of shares (100,000 units at $10.95), decreasing direct ownership by 4% to 1,077,197 units (SEC Form 4)

      4 - Roivant Sciences Ltd. (0001635088) (Issuer)

      5/22/25 9:00:37 PM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO Gline Matthew covered exercise/tax liability with 10,945 shares, decreasing direct ownership by 0.06% to 17,283,766 units (SEC Form 4)

      4 - Roivant Sciences Ltd. (0001635088) (Issuer)

      5/22/25 9:00:36 PM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ROIV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wolfe Research initiated coverage on Roivant Sciences with a new price target

      Wolfe Research initiated coverage of Roivant Sciences with a rating of Outperform and set a new price target of $17.00

      2/15/24 6:44:53 AM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Roivant Sciences with a new price target

      Piper Sandler initiated coverage of Roivant Sciences with a rating of Overweight and set a new price target of $20.00

      1/5/24 8:43:06 AM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Deutsche Bank initiated coverage on Roivant Sciences with a new price target

      Deutsche Bank initiated coverage of Roivant Sciences with a rating of Buy and set a new price target of $14.00

      12/12/23 8:08:23 AM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ROIV
    Leadership Updates

    Live Leadership Updates

    See more
    • Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600

      NEW YORK, March 26, 2024 /PRNewswire/ -- Roivant Sciences Ltd (NASD:ROIV) will replace Sunrun Inc. (NASD:RUN) in the S&P MidCap 400, and Sunrun will replace PGT Innovations Inc. (NYSE:PGTI) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, April 1. MITER Brands is acquiring PGT Innovations in a transaction expected to be completed on or about March 28 pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector April 1, 2024 S&P MidCap 400 Addition Roivant Sciences ROIV Health Care S&P MidCap 400 Deletion Sunrun RUN In

      3/26/24 6:22:00 PM ET
      $PGTI
      $ROIV
      $RUN
      $SPGI
      Building Products
      Industrials
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors

      BASEL, Switzerland and LONDON and NEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today announced the appointment of Mayukh Sukhatme, M.D., to its Board of Directors, effective immediately. Dr. Sukhatme will fill a newly created Class III seat on the Board of Directors, increasing the Board of Directors to eight members in total. "I'm thrilled to be adding Mayukh to our board. Mayukh has been with the company since almost the very beginning, and his contributions are too many to enumerate here. He has helped find and guide all of our key pipeline programs, and I am confident that his voice on our board will continue to further our important work for patients. It continue

      11/10/23 8:00:00 AM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Covant Therapeutics Appoints Vincent Hennemand as Chief Executive Officer

        BOSTON, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Covant Therapeutics, an innovative covalent drug discovery company, is pleased to announce the appointment of Vincent Hennemand as Chief Executive Officer (CEO). Vincent Hennemand is a seasoned executive with a distinguished career in the pharmaceutical and biotechnology industry. With an exceptional track record of leadership, a passion for advancing healthcare, novel classes of therapeutics, and in-depth experience in immunology therapies, Vincent is poised to guide Covant Therapeutics into a new era of growth, innovation, and patient-centric excellence. Vincent joins Covant Therapeutics from his previous role as COO at Intergalactic T

      10/13/23 8:00:00 AM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care